Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, comments on the United States District...
Revenue of $54.2 million, Adjusted EBITDA of $31.6 million and Cash from Operations of $26.4 million Received approval from Health Canada for Vascepa® to reduce the risk of cardiovascular events...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...
Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for reducing...
If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia TORONTO, Jan. 23, 2020 /CNW/ - HLS Therapeutics...